–Firm additionally Declares Participation in a Panel Dialogue on the 2021 Wedbush PacGrow Healthcare Convention
SAN DIEGO, Aug, 3, 2021 /PRNewswire/ — Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical firm centered on the invention and growth of modern medicines focusing on microRNAs (the “Firm” or “Regulus”), right now introduced that it’s going to report monetary outcomes and highlights for the quarter ended June 30, 2021 on Tuesday, August 10, 2021, after the U.S. monetary markets shut.
The Firm will host a convention name and stay audio webcast on Tuesday, August 10, 2021 at 5:00 p.m. Japanese Daylight Time to report its second quarter 2021 monetary outcomes and supply a company replace. To entry the decision, please dial (877) 257-8599 (home) or (970) 315-0459 (worldwide) and confer with convention ID 2825907. To entry the phone replay of the decision, dial (855) 859-2056 (home) or (404) 537-3406 (worldwide), passcode ID 2825907. The webcast and phone replay will likely be archived on the Firm’s web site at www.regulusrx.com following the decision.
Wedbush PacGrow Healthcare Convention
Moreover, the Firm introduced that Jay Hagan, President and Chief Government Officer, will take part in a panel on the 2021 Wedbush PacGrow Healthcare Convention on Wednesday, August 11, 2021, at 4:05 p.m. E.T.
A stay webcast of the panel will likely be out there on the investor relations part of the Firm’s web site at www.regulusrx.com. A replay of the webcast will likely be archived for 30 days following the presentation date.
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical firm centered on the invention and growth of modern medicines focusing on microRNAs. Regulus has leveraged its oligonucleotide drug discovery and growth experience to develop a pipeline complemented by a wealthy mental property property within the microRNA area. Regulus maintains its company headquarters in San Diego, CA.
Statements contained on this press launch relating to issues that aren’t historic info are “forward-looking statements” inside the that means of the Personal Securities Litigation Reform Act of 1995, together with statements related to the scientific actions in regards to the RGLS4326 program, together with the preliminary biomarker, pharmacokinetic and security information ensuing from the primary cohort of sufferers from the continuing scientific research, the sufficiency of the info required to recommence scientific research for prolonged length dosing, the timing of the Firm’s interactions with FDA relating to the scientific maintain, the timing and of different preclinical and scientific actions and the Firm’s anticipated money runway. As a result of such statements are topic to dangers and uncertainties, precise outcomes might differ materially from these expressed or implied by such forward-looking statements. Phrases akin to “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “purpose,” “potential” and comparable expressions are meant to establish forward-looking statements. These forward-looking statements are based mostly upon Regulus’ present expectations and contain assumptions which will by no means materialize or might show to be incorrect. Precise outcomes and the timing of occasions may differ materially from these anticipated in such forward-looking statements because of numerous dangers and uncertainties, which embrace, with out limitation, dangers related to the method of discovering, growing and commercializing medication which are secure and efficient to be used as human therapeutics and within the endeavor of constructing a enterprise round such medication, and suggestions from the FDA. As well as, whereas Regulus expects the COVID-19 pandemic to adversely have an effect on its enterprise operations and monetary outcomes, the extent of the impression on Regulus’ capacity to realize its preclinical and scientific growth targets and the worth of and marketplace for its frequent inventory, will rely upon future developments which are extremely unsure and can’t be predicted with confidence right now, akin to the last word length of the pandemic, journey restrictions, quarantines, social distancing and enterprise closure necessities within the U.S. and in different nations, and the effectiveness of actions taken globally to include and deal with the illness. These and different dangers are described in further element in Regulus’ filings with the Securities and Trade Fee. All forward-looking statements contained on this press launch converse solely as of the date on which they have been made. Regulus undertakes no obligation to replace such statements to mirror occasions that happen or circumstances that exist after the date on which they have been made.
View authentic content material to obtain multimedia:https://www.prnewswire.com/news-releases/regulus-therapeutics-announces-timing-for-second-quarter-2021-financial-results-webcast-and-conference-call-301347375.html
SOURCE Regulus Therapeutics Inc.